Welcome to our dedicated page for Milestone Pharmaceuticals news (Ticker: MIST), a resource for investors and traders seeking the latest updates and insights on Milestone Pharmaceuticals stock.
Milestone Pharmaceuticals Inc. (MIST) is a clinical-stage biopharmaceutical company pioneering patient-administered therapies for cardiovascular emergencies. This page serves as the definitive source for verified news and press releases related to MIST's innovative arrhythmia treatments, including etripamil nasal spray for PSVT and AFib-RVR management.
Investors and medical professionals will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated news collection provides essential insights into the company's scientific advancements while maintaining compliance with financial disclosure standards.
Key content categories include FDA submission updates, phase 3 trial results analysis, intellectual property developments, and executive leadership announcements. All materials are vetted for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to MIST's latest developments in rapid-onset cardiovascular therapies. Check regularly for updates on groundbreaking treatment models that combine medical innovation with patient empowerment.
Milestone Pharmaceuticals Inc. (MIST) reported its financial results for Q4 and the year ended December 31, 2021. The company had cash and equivalents of $114.1 million, down from $142.3 million the previous year. Research and development expenses rose significantly to $10.9 million in Q4, contributing to a total operating loss of $42.9 million for 2021. Milestone is focused on the upcoming Phase 3 RAPID trial results for its cardiovascular drug etripamil, with topline data expected mid-second half of 2022, targeting supraventricular tachycardia treatment.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced its participation in two upcoming investor conferences. Management will present at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 2:10 p.m. ET, and at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 11:20 a.m. ET. Live webcasts of these presentations will be available on Milestone's website, with archived replays accessible for 90 days post-event. Milestone focuses on innovative cardiovascular medicines, with its lead candidate, etripamil, in Phase 3 trials for paroxysmal supraventricular tachycardia.
Milestone Pharmaceuticals (Nasdaq: MIST) appointed David Bharucha, M.D., Ph.D., as Chief Medical Officer, effective February 15, 2022. Dr. Bharucha, a cardiac electrophysiologist with over 30 years of experience, replaces Francis Plat, M.D., who will transition to Chief Scientific Officer and serve in an advisory role post-Phase 3 RAPID trial. Dr. Bharucha aims to advance etripamil, a treatment for paroxysmal supraventricular tachycardia and atrial fibrillation. An inducement stock option for 330,000 shares has been granted to him, aligning his interests with shareholder value.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that CEO Joseph Oliveto will participate in a prerecorded fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The chat will be available on January 10, 2022, at 7:00 am ET on Milestone's website. Milestone focuses on innovative cardiovascular medicines, with its lead product, etripamil, in Phase 3 trials for paroxysmal supraventricular tachycardia and Phase 2 trials for atrial fibrillation.
Milestone Pharmaceuticals (Nasdaq: MIST) announced significant findings from a post-hoc analysis of the Phase 3 NODE-301 trial for etripamil, a novel nasal spray treatment for paroxysmal supraventricular tachycardia (PSVT). The analysis revealed that etripamil significantly reduced heart rates during SVT episodes within 5 minutes, sustained for up to 60 minutes. Notably, patients experienced greater heart rate reductions compared to placebo (p<0.0001). These results, presented at the AHA Scientific Sessions 2021, support etripamil’s potential as an effective at-home treatment for PSVT and possibly atrial fibrillation with rapid ventricular response.
Milestone Pharmaceuticals (MIST) reported its Q3 2021 financial results, highlighting progress in the etripamil program for PSVT. The Phase 3 RAPID trial is on track to report topline data in H2 2022, targeting 180 adjudicated events among 500 patients. The recent PRO market research study revealed significant disease burden among PSVT patients, with a median of 12-15 episodes annually. The company holds $126.4 million in cash and reported a Q3 operating loss of $14.3 million, an increase from the previous year.
Milestone Pharmaceuticals (Nasdaq: MIST) announced presentations by CEO Joseph Oliveto at key investor conferences. The 2021 Jefferies London Virtual Healthcare Conference presentation becomes available on-demand on November 18, 2021, at 3:00 a.m. ET. Additionally, at the Piper Sandler 33rd Annual Virtual Healthcare Conference, a fireside chat will be accessible starting at 10:00 a.m. ET on November 22, 2021. Replays will be found on Milestone's website for approximately 30 days after the events, reinforcing their commitment to innovative cardiovascular medicine.
Milestone Pharmaceuticals (Nasdaq: MIST) has announced that Amit Hasija, CFO, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on September 29, 2021, at 10:00 a.m. ET. The presentation will occur virtually, and a live webcast can be accessed on Milestone's website, with an archived replay available afterward. Milestone is developing innovative cardiovascular medicines, including etripamil, which is in Phase 3 for treating paroxysmal supraventricular tachycardia and in Phase 2 for atrial fibrillation.
Milestone Pharmaceuticals (Nasdaq: MIST) announced that CEO Joseph Oliveto will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The chat will be pre-recorded and accessible from September 13, 2021, at 7:00 am ET on Milestone's website. Milestone focuses on innovative cardiovascular medicines, with its lead product candidate, etripamil, in Phase 3 trials for paroxysmal supraventricular tachycardia and in Phase 2 trials for atrial fibrillation treatment.
Milestone Pharmaceuticals (MIST) reported Q2 2021 financial results, highlighting a revenue of $15 million from an exclusive license agreement. As of June 30, the company had $135.8 million in cash and investments. Operating income reached $0.7 million, a significant improvement from a loss of $13.1 million in Q2 2020. Progress continues in clinical trials for etripamil, with increasing enrollment rates for the Phase 3 RAPID trial and positive potential indicated for AFib-RVR treatment. The company remains on track to report topline data in H2 2022.
FAQ
What is the current stock price of Milestone Pharmaceuticals (MIST)?
What is the market cap of Milestone Pharmaceuticals (MIST)?
